ELISA/assay

Mouse PCSK9 ELISA Kit

MBS824483

96 Tests

470 USD

ELISA Kit

Mouse PCSK9 ELISA Kit

PCSK9

NARC1; Proprotein convertase subtilisin/kexin type 9; Neural apoptosis-regulated convertase 1; NARC-1; Proprotein convertase 9; PC9; Subtilisin/kexin-like protease PC9

proprotein convertase subtilisin/kexin type 9; Proprotein convertase subtilisin/kexin type 9; proprotein convertase subtilisin/kexin type 9; NARC-1; proprotein convertase 9; proprotein convertase PC9; subtilisin/kexin-like protease PC9; neural apoptosis regulated convertase 1; neural apoptosis-regulated convertase 1; proprotein convertase subtilisin/kexin type 9; Neural apoptosis-regulated convertase 1; NARC-1; Proprotein convertase 9; PC9; Subtilisin/kexin-like protease PC9

PCSK9

Pcsk9; Pcsk9; FH3; PC9; Narc1; HCHOLA3; AI415265; AI747682; Narc1; NARC-1; PC9

PCSK9_MOUSE

Mouse

694

The Mouse PCSK9 ELISA Kit allows for the detection and quantification of endogenous levels of natural and/or recombinant Mouse PCSK9 proteins within the range of 156 pg/ml - 10000 pg/ml.

Shipped and store at 4 degree C for 6 months, store at -20 degree C for one year. Avoid freeze/thaw cycles.

Sandwich ELISA (SE)

Samples: Cell Culture Supernatants, Serum, Plasma. Sensitivity: 10 pg/ml.

Principle of the Assay The Bioscience Mouse PCSK9 ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of Mouse PCSK9 in Cell Culture Supernatants, Serum, Plasma. This assay employs an antibody specific for Mouse PCSK9 coated on a 96-well plate. Standards and samples are pipetted into the wells and PCSK9 present in a sample is bound to the wells by the immobilized antibody. The wells are washed and biotinylated anti-Mouse PCSK9 antibody is added. After washing away unbound biotinylated antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of PCSK9 bound. The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm. Background/Introduction: Proprotein convertase subtilisin/kexin type 9, also known as PCSK9, is an enzyme that in humans is encoded by the PCSK9 gene. This gene encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. By genomic sequence analysis, the PCSK9 gene was mapped to chromosome 1p32. This protein plays a major regulatory role in cholesterol homeostasis. PCSK9 binds to the epidermal growth factor-like repeat A (EGF-A) domain of the low-density lipoprotein receptor (LDLR), inducing LDLR degradation. Reduced LDLR levels result in decreased metabolism of low-density lipoproteins (LDL), which could lead to hypercholesterolemia. PCSK9 may also have a role in the differentiation of cortical neurons.

23956352

NP_705793.1

NM_153565.2

Q80W65

74,823 Da

PCSK9: Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways. Defects in PCSK9 are the cause of hypercholesterolemia autosomal dominant type 3 (HCHOLA3). A familial condition characterized by elevated circulating cholesterol contained in either low-density lipoproteins alone or also in very-low-density lipoproteins. Belongs to the peptidase S8 family. 2 isoforms of the human protein are produced by alternative splicing. Protein type: EC 3.4.21.-; Cell development/differentiation; Secreted; Secreted, signal peptide; Protease. Cellular Component: Golgi apparatus; extracellular space; cell surface; rough endoplasmic reticulum; lysosome; endoplasmic reticulum; early endosome; extracellular region; ER to Golgi transport vesicle; perinuclear region of cytoplasm; cytoplasm; late endosome; plasma membrane; endosome. Molecular Function: peptidase activity; very-low-density lipoprotein binding; sodium channel inhibitor activity; protein self-association; hydrolase activity; low-density lipoprotein receptor binding; serine-type peptidase activity; serine-type endopeptidase activity; low-density lipoprotein binding; apolipoprotein binding; apolipoprotein receptor binding. Biological Process: steroid metabolic process; cholesterol metabolic process; lysosomal transport; apoptosis; positive regulation of receptor internalization; lipoprotein metabolic process; regulation of low-density lipoprotein receptor catabolic process; proteolysis; cellular response to starvation; neuron differentiation; protein autoprocessing; cholesterol homeostasis; triacylglycerol metabolic process; cellular response to insulin stimulus; phospholipid metabolic process; positive regulation of neuron apoptosis; regulation of neuron apoptosis; negative regulation of receptor recycling; low-density lipoprotein receptor catabolic process; protein processing; regulation of receptor activity; lipid metabolic process; low-density lipoprotein receptor metabolic process

96 Tests

470 USD